(a) a nucleotide sequence coding for the amino acid sequence (SEQ ID NO: 23)

Y C L (X_1 . . . X_n) S A R Q L T F

in which X_1 . . . X_n represents a sequence 3-4 of amino acids, wherein the amino acid sequence X_1 . . . X_n is selected from the group consisting of the amino acid sequences VGG (SEQ. ID NO: 46), VLSG (SEQ. ID NO: 47), ATG (SEQ. ID NO: 48), VSG (SEQ. ID NO: 49), DSG (SEQ. ID NO: 50), VVSG (SEQ. ID NO. 51), ALAG (SEQ. ID NO: 52), APSG (SEQ. ID NO: 53) and VGR SEQ. ID NO: 54), and

(b) a nucleotide sequence which codes for an amino acid sequence with an equivalent recognition specificity, as achieved with a T cell receptor comprising a CDR3 region with the amino acid sequence of SEQ ID NO. 23, for the peptide component of the T cell receptor ligands;

wherein the CDR3 region is at least 90% identical with the amino sequence of (a).

4. (Four Times Amended) A Nucleic acid as claimed in claim 2 wherein the amino acid sequence X_1 . . . X_n is selected from the group consisting of amino acid sequences VGG (SEQ. ID NO: 46), VLSG (SEQ. ID NO: 47) and ATG (SEQ. ID NO: 48).

5. (Three Times Amended) A vector,

wherein

it contains at least one copy of a nucleic acid as claimed in one of the claims 1 to 4.

7. (Four Times Amended) A cell,

wherein

I4 it is transformed with a nucleic acid as claimed in one of the claims 1 to 4 or with a vector as claimed in claim 5.

26. (Four Times Amended) A pharmaceutical composition which contains

I5 as an active component a nucleic acid as claimed in one of the claims 2 or 4, or a cell as claimed in claim 6 or 7 optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.

45. (Amended) An isolated nucleic acid of claim 2 wherein the nucleic acid is

I6 purified.

46. (Amended) A nucleic acid as claimed in claim 2 wherein the CDR3 region

I7 is (a).